Foundayo Orforglipron Application Scope

Foundayo is indicated, in combination with a reduced‑calorie diet and increased physical activity, for:
• Adults with obesity (BMI ≥30 kg/m²)
• Adults who are overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbid condition (e.g., hypertension, type 2 diabetes)
to reduce excess body weight and help sustain weight loss over the long term.

Orforglipron Characteristics

Ingredients: Orforglipron (as orforglipron calcium)
Properties: Orforglipron is a small‑molecule, oral GLP‑1 receptor agonist that reduces appetite and supports weight loss.
Packaging Specification: Tablets available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, each with distinct color and marking.
Storage: Store at 68–77°F (20–25°C); permissible short excursions to 59–86°F (15–30°C). Keep in original bottle/carton, protect from light.
Expiry Date: Refer to the product carton/bottle expiration date.
Executive Standard: U.S. Food and Drug Administration (FDA) approved
Approval Number: Detailed regulatory numbers vary by market; in the U.S., refer to the FDA label/labeling database.
Date of Revision: Latest label revisions align with April 2026 FDA approval
Manufacturer: Eli Lilly and Company

Guidelines for the Use of Foundayo

Dosage and Administration:
- Recommended Dose: Start with 0.8 mg once daily and titrate upward at ~30‑day intervals based on tolerability: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (maximum). Each dose should be taken for at least 30 days before increasing.
- Administration: Take once daily, at any time of day, with or without food or water. Swallow the tablet whole; do not chew, crush, or split.
- Missed Dose: If a dose is missed, take it as soon as remembered. Do not take a double dose to make up for a missed one. If missed for 7 consecutive days or more, resume at a lower dose and re‑titrate to reduce gastrointestinal side effects.
Adverse Reactions:
- Common Adverse Reactions: The most frequently reported side effects include nausea, vomiting, diarrhea or constipation, indigestion, abdominal pain, headache, gas, heartburn, fatigue, bloating, and in some cases hair loss.
- Serious Adverse Reactions: Serious but rare adverse reactions may include thyroid C‑cell tumors, pancreatitis, gallbladder disorders, severe gastrointestinal events, hypoglycemia (especially when combined with insulin or sulfonylureas), and serious allergic reactions including anaphylaxis.
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to orforglipron or excipients
Precautions:
- Not studied in children; safety not established.
- Could delay gastric emptying — inform surgical team before procedures.
- Monitor for dehydration due to GI effects.
- Discuss all concomitant medications (including contraceptives, statins, etc.) — interactions possible.
- Pregnant or breastfeeding individuals should consult clinicians.

Orforglipron Interactions

May interact with drugs affected by gastric emptying.
Specific interactions (e.g., simvastatin, contraceptives) noted in some label discussions — clinical guidance required.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.